The combination of ethinylestradiol/cyproterone acetate is temporarily withdrawn from the market in France. Is the measure justified?

European Journal of Contraception and Reproductive Health Care

Volumn 18, Issue 2, 2013, Pages 75-78

  Chabbert Buffet, Nathalie ^a   Amy, Jean Jacques ^b  

^a UNIVERSITÉ PARIS EST   (France)

^b European Journal of Contraception and Reproductive Health Care ^*  (United Kingdom)

Author keywords

Acne; Contraception; Diane 35; France; Hirsutism; Thrombosis; Venous thromboembolism

Indexed keywords

C REACTIVE PROTEIN; CYPROTERONE ACETATE; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL; DROSPIRENONE; ETHINYLESTRADIOL; GESTAGEN;

ACNE; BLOOD LEVEL; BRAIN ISCHEMIA; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MARKETING; DRUG WITHDRAWAL; FRANCE; HIRSUTISM; HUMAN; HYPERANDROGENISM; LUNG EMBOLISM; NETHERLANDS; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; SEBORRHEA;

CONTRACEPTIVES, ORAL, COMBINED; DRUG INDUSTRY; FEMALE; FRANCE; HUMANS; SAFETY-BASED DRUG WITHDRAWALS;

EID: 84875134183     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2013.780203     Document Type: Review

References (12)

1. Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343: d6423.
2. Mintzes B, Morgan S, Bassett KL. Medicine by media: Did acritical television documentary affect the prescribing of cyproterone-estradiol (Diane-35)? CMAJ 2005; 173: 1313-5. (Authors' note: the title of this paper does indeed mention estradiol, instead of ethinylestradiol.
3. Erdmann D, Schindler EM, Schindler AE. [Ovarian suppression with Diane 35/50]. Geburtshilfe Frauenheilkd 1994; 54: 627-33. [In German]
4. Murcia JM, Esparza ML. [Case report article: ovulation and Diane-35, current perspectives in detection and control of fertility]. Rev Med Univ Navarra 2006; 50: 26-9. [In Spanish]
5. Bruni V, Dei M. Hyperandrogenic conditions in the adolescent. In Amy JJ, ed. Paediatric and adolescent gynaecology . Amsterdam: Elsevier 2003: 163-77.
6. Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: An Endocrine Society Clinical Practice Guideline. JClin Endocrinol Metab 2008; 93: 1105-20.
7. Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003; 4: CD001125.
8. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 7: CD004425.
9. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
10. Martínez F, Ramírez I, Pérez-Campos E, et al. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur JContracept Reprod Health Care 2012; 17: 7-29.
11. Raps M, Helmerhorst F, Fleischer K, et al. Sex hormonebinding globulin as amarker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost 2012; 10: 992-7.
12. Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. JThromb Haemost 2004; 2: 1594-600.